Roivant Sciences (ROIV) Common Equity (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Common Equity came in at $4.5 billion in Q1 2026, down 3.42% YoY from $4.7 billion in Q1 2025, and down 8.98% on a QoQ basis from $5.0 billion in Q4 2025.
Roivant Sciences (ROIV) Common Equity (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 7 years of Common Equity data on file, last reported at $4.5 billion in Q1 2026.
- Quarterly Common Equity fell 3.42% year-over-year to $4.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 billion (down 3.42% YoY) and the FY2026 annual result came in at $4.5 billion, down 3.42% from the prior year.
- Common Equity retreated to $4.5 billion in Q1 2026, from $5.0 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $6.6 billion in Q4 2023 to a low of $1.3 billion in Q3 2023.
- A 5-year average of $3.8 billion and a median of $4.7 billion in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity plunged 37.65% — and 2023, when it jumped 361.38%.
- Tracing ROIV's Common Equity over 5 years: stood at $1.4 billion in 2022, then surged by 361.38% to $6.6 billion in 2023, then decreased by 15.93% to $5.5 billion in 2024, then dropped by 10.15% to $5.0 billion in 2025, then decreased by 8.98% to $4.5 billion in 2026.
- The last three Common Equity figures came in at $4.5 billion (Q1 2026), $5.0 billion (Q4 2025), and $4.8 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.92 Bn |
| Mar 31, 2026 | 4.53 Bn |
| Dec 31, 2025 | 4.97 Bn |
| Sep 30, 2025 | 4.81 Bn |
| Jun 30, 2025 | 4.82 Bn |
| Mar 31, 2025 | 4.69 Bn |
| Dec 31, 2024 | 5.54 Bn |
| Sep 30, 2024 | 5.58 Bn |
| Jun 30, 2024 | 5.90 Bn |
| Mar 31, 2024 | 6.45 Bn |
| Dec 31, 2023 | 6.58 Bn |
| Sep 30, 2023 | 1.33 Bn |
| Jun 30, 2023 | 1.33 Bn |
| Mar 31, 2023 | 1.61 Bn |
| Dec 31, 2022 | 1.43 Bn |
| Sep 30, 2022 | 1.51 Bn |
| Jun 30, 2022 | 1.76 Bn |
| Mar 31, 2022 | 2.04 Bn |
| Dec 31, 2021 | 2.25 Bn |
| Sep 30, 2021 | 2.43 Bn |